ChabioTech announced on May 15 that it recorded consolidated revenue of 329.7 billion won in the first quarter of 2026, an 8% increase compared to the same period last year.
The company attributed its stable growth in global healthcare operations across the United States, Australia, Singapore, and Japan, along with the integration effects from Kakao Healthcare and Chai AI Healthcare. The growth of key subsidiaries, including CMG Pharmaceutical and Chacares, also contributed to the revenue increase.
However, the company reported an operating loss of 30.7 billion won, primarily due to investments in expanding its digital healthcare business and research and development in advanced regenerative medicine. The net loss for the period was 2.6 billion won, reflecting a reduction in the deficit by 24.4 billion won compared to the previous year, influenced by portfolio restructuring and asset efficiency improvements.
On a standalone basis, revenue rose by 9% to 16.2 billion won, driven by growth in IT, biotechnology, and cord blood-related businesses. Notably, the IT sector continued to grow due to the expansion of digital healthcare infrastructure and increased projects for smart hospital systems.
Standalone operating losses amounted to 1.4 billion won, impacted by increased research and development investments. However, due to the sale of shares in Solidus Investment, the net profit turned positive at 20.8 billion won.
ChabioTech's digital healthcare platform integrates the entire process for foreign patients residing abroad to receive consultations and follow-up care from domestic medical professionals. The company plans to accelerate the enhancement of its digital healthcare business model linked to medical, healthcare, and clinical data, as well as secure growth drivers based on regenerative medicine and AI.
Meanwhile, ChabioTech is advancing the development of key pipelines, including the gene therapy for idiopathic pulmonary fibrosis, 'CHAGE-201-IPF', the allogeneic CAR NK cell therapy 'CHACAR-NK-201', and the cell therapy for ovarian insufficiency, 'CHAUM-101'.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.